Post-COVID-19 Inflammatory Arthritis Treated With Upadacitinib: A Case Report
Cherie S Zhi, Ami Ben-Artzi
TL;DR
This case report shows that upadacitinib effectively treats inflammatory arthritis that occurs after a COVID-19 infection.
Contribution
The report demonstrates the clinical effectiveness of upadacitinib in treating post-COVID-19 inflammatory arthritis.
Findings
Two patients with post-COVID-19 inflammatory arthritis showed meaningful clinical improvement with upadacitinib.
Upadacitinib was associated with reduced inflammation markers and symptom relief in treated patients.
Abstract
Two patients who developed inflammatory arthritis following COVID-19 infection are presented, characterized by arthralgias, arthritis, and elevated markers of inflammation (C-reactive protein). Both patients had clinically meaningful responses to treatment with upadacitinib, a Janus Kinase inhibitor (JAKi). This case report highlights the efficacy and safety of upadacitinib in the treatment of post-COVID-19 inflammatory arthritis.
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsRheumatoid Arthritis Research and Therapies · Spondyloarthritis Studies and Treatments · Autoimmune and Inflammatory Disorders Research